Gen-Probe gets FDA OK for Aptima HIV test

GabrielMadway

SAN FRANCISCO (MarketWatch) -- Gen-Probe Inc.
GPRO, +1.31%
said late Thursdayu it has received Food and Drug Administration marketing approval for its Aptima HIV-1 RNA test. The San Diego-based company said the test can be used as an aid in the diagnosis of acute and primary HIV-1 infection, and to confirm HIV-1 infection in people whose specimen is repeatedly positive for HIV-1 antibodies. Gen-Probe expects to launch the test in November in conjunction with its Aptima test for hepatitis C.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.